Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17872158 | 0.85 | KMT2A (0.43) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17872164 | 0.80 | NTRK1 (0.60) | — | |
| SCHEMBL17872102 | 0.78 | KMT2A (0.44) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17872157 | 0.74 | MAPT (0.41) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29574061 | 0.74 | CDK7 (0.46) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1204604 | 0.74 | C5AR1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4290936 | 0.74 | MAPT (0.45) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17878628 | 0.73 | MAPT (0.41) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17878748 | 0.73 | MAPT (0.43) | KMT2AMEN1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4280181 | 0.72 | ALDH1A1 (0.44) | KMT2AMEN1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3236959-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| EP-3236959-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Dana Farber Cancer Institute, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105528-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | KMT2A 1373/4885MEN1 600/4885NPC1 4352/4885 |
| US-20220024929-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | KMT2A 1373/4885MEN1 600/4885NPC1 4352/4885 |
| US-20190055248-A1 | INHIBITORS OF CYCLINDEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | KMT2A 886/4885MEN1 742/4885NPC1 4426/4885 |
| US-20210115051-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | KMT2A 1373/4885MEN1 600/4885NPC1 4352/4885 |
| US-10870651-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | KMT2A 1373/4885MEN1 600/4885NPC1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.